Merck’s fourth-quarter results top estimates, fueled by key cancer drugs and vaccines

Merck on Thursday reported fourth-quarter earnings and sales that beat analyst expectations, powered by strong growth in cancer and vaccine products.

Previous post Trump’s first-term agenda was thwarted by bureaucrats. Here’s conservatives’ plan to avoid a repeat.
Next post Treasury yields inch higher after Powell’s rate-cut pushback and as jobs data looms